A detailed history of Wells Fargo & Company transactions in Rx Sight, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 26,129 shares of RXST stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,129
Previous 48,055 45.63%
Holding current value
$1.2 Million
Previous $2.89 Million 55.34%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$40.78 - $57.04 $894,142 - $1.25 Million
-21,926 Reduced 45.63%
26,129 $1.29 Million
Q2 2024

Aug 13, 2024

BUY
$50.42 - $64.29 $611,997 - $780,352
12,138 Added 33.79%
48,055 $2.89 Million
Q1 2024

May 10, 2024

BUY
$35.51 - $57.92 $397,392 - $648,182
11,191 Added 45.26%
35,917 $1.85 Million
Q4 2023

Feb 09, 2024

SELL
$20.91 - $40.9 $34,752 - $67,975
-1,662 Reduced 6.3%
24,726 $996,000
Q3 2023

Nov 13, 2023

SELL
$27.05 - $33.37 $48,365 - $59,665
-1,788 Reduced 6.35%
26,388 $735,000
Q2 2023

Aug 15, 2023

BUY
$16.37 - $28.9 $150,587 - $265,851
9,199 Added 48.47%
28,176 $811,000
Q1 2023

May 12, 2023

BUY
$12.58 - $16.68 $69,403 - $92,023
5,517 Added 40.99%
18,977 $316,000
Q4 2022

Feb 13, 2023

SELL
$9.93 - $14.2 $49,580 - $70,900
-4,993 Reduced 27.06%
13,460 $170,000
Q3 2022

Nov 14, 2022

SELL
$11.19 - $15.85 $46,304 - $65,587
-4,138 Reduced 18.32%
18,453 $222,000
Q2 2022

Aug 12, 2022

SELL
$10.61 - $16.66 $136,869 - $214,914
-12,900 Reduced 36.35%
22,591 $318,000
Q1 2022

May 16, 2022

BUY
$8.97 - $14.03 $16,531 - $25,857
1,843 Added 5.48%
35,491 $440,000
Q4 2021

Feb 14, 2022

BUY
$9.52 - $13.81 $69,105 - $100,246
7,259 Added 27.51%
33,648 $379,000
Q3 2021

Nov 15, 2021

BUY
$11.85 - $17.32 $312,709 - $457,057
26,389 New
26,389 $334,000

Others Institutions Holding RXST

About RxSight, Inc.


  • Ticker RXST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 27,638,900
  • Market Cap $1.27B
  • Description
  • RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. T...
More about RXST
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.